πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 120 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10196424

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10166288

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130705

Vaccines with interleukin-33 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106592

Interleukin-4 receptor-binding fusion proteins and uses thereof

Medicenna Therapeutics Inc. Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10093708

Interleukin-4 receptor-binding fusion proteins and uses thereof

Medicenna Therapeutics Inc. Β· Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072086

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10035824

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023614

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005834

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9840558

Human antibody specific for interleukin-1alpha

XBIOTECH INC. Β· Granted Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9669091

Vaccines having an antigen and interleukin-23 as an adjuvant

Inovio Pharmaceuticals, Inc. Β· Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9624268

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9487590

Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

CytomX Therapeutics, Inc. Β· Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475839

Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9339528

Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 recept

GENERAL REGENERATIVES, LTD. Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9238692

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9173880

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9084761

Use of interleukin-15 to treat cardiovascular diseases

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS Β· Granted Tue Jul 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9045559

Method for screening inhibitors of interleukin-32 (IL-32)

The Regents of the University of Colorado Β· Granted Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8962814

Interleukin-1Ξ± antibodies and methods of use

XBIOTECH INC. Β· Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8945559

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8603456

Method of treating hair loss with compositions containing interleukin-1

United Technologies UT AG Β· Granted Tue Dec 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8556882

Inducible interleukin-12

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 15 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8388969

Interleukin-1 alpha antibodies and methods of use

XBIOTECH INC. Β· Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted